Drugs / L-Annamycin
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06788756 Comparator | Mar 2025 → Aug 2029 expected | acute myeloid leukemia | Moleculin Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Annamycin | “190 mg/m2/day L-Annamycin for Injection for three consecutive days in combination with 2.0 g/m2/day Cytarabine Injection for five consecutive days.” NCT06788756 ↗ |
| Route | Intravenous | “L-Annamycin for Injection will be administered as an intravenous (IV) infusion over 2 hours.” NCT06788756 ↗ |